Aurinia Pharmaceuticals (AUPH) Operating Leases (2020 - 2026)

Aurinia Pharmaceuticals' Operating Leases history runs 7 years deep, the most recent figure standing at $2.3 million for Q1 2026.

• Quarterly Operating Leases fell 58.14% year-over-year to $2.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.3 million (down 58.14% YoY) and the FY2025 annual result came in at $4.9 million, down 14.68% from the prior year.
• Operating Leases was $2.3 million for Q1 2026 at Aurinia Pharmaceuticals, down from $4.9 million in the prior quarter.
• Across five years, Operating Leases topped out at $7.8 million in Q2 2023 and bottomed at $2.3 million in Q1 2026.
• A 5-year average of $6.3 million and a median of $6.5 million in 2023 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2023 — Operating Leases advanced 5.82% — and 2026, when it slumped 58.14%.
• Aurinia Pharmaceuticals' Operating Leases stood at $7.2 million in 2022, then declined by 8.7% to $6.5 million in 2023, then declined by 12.05% to $5.7 million in 2024, then fell by 14.68% to $4.9 million in 2025, then sank by 52.69% to $2.3 million in 2026.
• Business Quant data shows AUPH's Operating Leases at $2.3 million in Q1 2026, $4.9 million in Q4 2025, and $5.1 million in Q3 2025.